Moderna Inc MRNA is getting a big boost in Tuesday's after-hours session following a positive development on the company's coronavirus vaccine. What Happened? Moderna's vaccine drug shows "induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine." The 45 enrolled participants in the Phase 1 clinical trial of the mRNA-1273 SARS-CoV-2 vaccine received their first vaccination between March 16 and April 14, 2020.